购物车
- 全部删除
- 您的购物车当前为空
Stamulumab (MYO-029)是一种重组人IgG1λ抗体,能与肌肉生长抑制素(myostatin)结合,通过阻断与其内源性高亲和力受体ActRIIB的结合,来中和myostatin的活性。在SCID小鼠中,Stamulumab主要引起肌纤维肥大,而非增生,并展现出对贝克尔肌营养不良症(BMD)、面肩肱型营养不良症(FSHD)及肢带型肌营养不良症(LGMD)研究的应用潜力。
Stamulumab (MYO-029)是一种重组人IgG1λ抗体,能与肌肉生长抑制素(myostatin)结合,通过阻断与其内源性高亲和力受体ActRIIB的结合,来中和myostatin的活性。在SCID小鼠中,Stamulumab主要引起肌纤维肥大,而非增生,并展现出对贝克尔肌营养不良症(BMD)、面肩肱型营养不良症(FSHD)及肢带型肌营养不良症(LGMD)研究的应用潜力。
产品描述 | Stamulumab (MYO-029), a recombinant human IgG1λ antibody, targets and neutralizes myostatin by inhibiting its interaction with the ActRIIB receptor, leading to muscle fiber hypertrophy rather than hyperplasia in SCID mice. This compound shows research potential for treating disorders such as Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) [1] [2]. |
CAS No. | 705287-60-1 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容